Your Cells Are Running Out of Currency — NAD+ and the Peptides That May Change That

You're 47, sleep is decent, training is consistent, diet is clean. But recovery takes longer than it did five years ago, focus drifts by mid-afternoon, and the bloodwork your doctor calls "fine" doesn't match how you feel. The conventional answer is to age more gracefully. The longevity medicine answer is to look at what's happening inside the mitochondria.

NAD+ (nicotinamide adenine dinucleotide) is where that conversation increasingly starts — and where certain peptides have begun entering the same protocols.

What NAD+ Depletion Actually Looks Like in Numbers

NAD+ levels in human tissue decline measurably with age. A 2013 study by Gomes et al. in Cell found that NAD+ concentrations in skeletal muscle drop by roughly 50% between the ages of 20 and 50 in mice — and subsequent human tissue studies have supported comparable directional trends. By the time most people are seeking out longevity clinics, their cellular NAD+ availability is a fraction of what it was at peak biological performance.

That depletion matters because NAD+ is the substrate that fuels sirtuins — a family of proteins governing DNA repair, inflammation regulation, and mitochondrial biogenesis. Without adequate NAD+, sirtuins effectively stall. PARP enzymes, which repair DNA strand breaks, also depend on NAD+ and can rapidly exhaust local supplies during oxidative stress. The cascade effects of chronic low NAD+ map directly onto the symptoms described above: slower tissue repair, cognitive fatigue, reduced metabolic flexibility.

The NMN and NR Baseline — and Why Peptides Are Being Added

Most longevity-focused protocols start with NAD+ precursors — nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR). Both convert to NAD+ through salvage pathways. Standard NMN dosing in clinical trials has typically run between 250 mg and 500 mg daily. A 2020 randomised controlled trial by Yoshino et al. in Cell Metabolism (n=25) found that 250 mg/day of NMN over 10 weeks improved muscle insulin sensitivity in postmenopausal women with prediabetes, without significant adverse effects.

Oral precursors have a ceiling. Gut conversion is variable, and tissue uptake doesn't distribute evenly across compartments. IV NAD+ infusions, offered at US longevity clinics at $400 to $900 per session depending on dosage and location, bypass the gut entirely. A typical infusion protocol runs 500 mg to 1,000 mg administered over two to four hours.

This is where regenerative peptides have started appearing in the same protocol stack — not as NAD+ replacements, but as agents that may amplify the cellular environment NAD+ is working in.

How Peptides Like BPC-157 Intersect With Cellular Repair

BPC-157 is the peptide most frequently discussed alongside NAD+ in clinical longevity contexts. Its mechanism centres on upregulating nitric oxide pathways and promoting angiogenesis — processes that increase blood flow to tissues undergoing repair. The working hypothesis among practitioners running combined protocols is that improved tissue perfusion makes NAD+-dependent repair processes more efficient: better substrate delivery, higher mitochondrial oxygen utilisation, and faster clearance of damaged cells.

BPC-157 is typically administered at 250–500 mcg per day, either subcutaneously or via injection into target tissue. It remains unscheduled in most jurisdictions and outside approved pharmaceutical pathways in the US, dispensed through compounding pharmacies on a prescription basis. Most online peptide programs include it as an optional add-on to broader stacks rather than a standalone protocol.

Growth hormone secretagogues like CJC-1295 and sermorelin also appear in NAD+-adjacent protocols because growth hormone plays a direct role in cellular repair and metabolic efficiency — both functions NAD+ supports at the enzymatic level. Optimising the hormonal environment gives NAD+ repletion more to work with.

What the Evidence Actually Supports — and What Remains Theoretical

The honest accounting: NAD+ precursor supplementation has the strongest human trial evidence of anything in this stack. The Yoshino et al. RCT is the most rigorous human data point; earlier work by Elhassan et al. in Nature Communications (2019, n=12) showed NR at 1,000 mg/day raised NAD+ in blood and muscle in healthy older men, though without the metabolic outcome measures of the Yoshino trial.

The BPC-157 human data is sparse. Mechanism work is primarily from rodent models, and no large-scale RCTs in humans had been completed as of mid-2026. Practitioners cite clinical observation accumulated over years of use, but that is not controlled trial evidence.

IV NAD+ has practitioner and patient reports of cognitive clarity and energy improvements, but peer-reviewed outcome data remains limited. The FDA has not approved NAD+ infusions for any specific indication. The sirtuin activation story — compelling in biochemistry — has been harder to operationalise into measurable clinical outcomes than early researchers expected.

What the evidence does support: NAD+ declines with age, precursors raise it, and raising it has shown metabolic benefit in at least two published human studies. Everything beyond that is either mechanistically plausible or observationally reported — which describes most of longevity medicine's current frontier.

Finding Protocols That Match What You're Actually Trying to Fix

The practical question is whether a clinic is running NAD+ and peptide protocols in a way that makes biochemical sense for your specific markers — not simply selling a pre-built stack. Clinics worth evaluating will draw baseline bloodwork including NAD+ metabolomics where available, assess mitochondrial function markers such as lactate-to-pyruvate ratio or VO₂ max, and adjust dosing based on response rather than running every patient through an identical six-week protocol.

System Labs and Yucca Health are among the US telehealth platforms currently offering structured longevity stacks that incorporate NAD+ precursors alongside peptide protocols, with physician oversight built into the intake process. For broader options, the peptide clinics directory covers both US and international providers.

The Specific Takeaway

If your goal is cellular regeneration rather than acute symptom relief, the highest-evidence starting point is NMN at 250–500 mg daily with baseline metabolic bloodwork — fasting insulin, HbA1c, and NAD+ metabolomics if available — to track response. IV NAD+ at 500–1,000 mg per session is a logical next step if oral protocols plateau after eight to twelve weeks. Peptides like BPC-157 make mechanistic sense as adjuncts, particularly for tissue repair, but belong as additions to a working foundation rather than the foundation itself. The stack earns its cost when each layer is justified by your own data — not by a protocol designed for someone else's markers.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---